The effect of intramuscular diclofenac or placebo on analgesia obtained and on opiate and antiemetic requirements was observed in a randomised double-blind study of sixty patients receiving continuous intravenous papaveretum. Those patients receiving diclofenac required less papaveretum (P = 0.001) than those receiving placebo.
Hodsman et al. 10 and most recently by Moffat et at. II showed significant reductions in morphine requirements when diclofenac was administered concurrently by intramuscular injection whereas Coloquhoun and Fell l2 were unable to demonstrate this following rectal administration of diclofenac after cholecystectomy.
The benefit of non-steroidal anti-inflammatory drugs after orthopaedic surgery is less in dispute.
Recently McGlew et at. showed that rectal indomethacin was an effective analgesic after spinal surgery. Although an anti-platelet effect with a significant increase in bleeding time was demonstrated, there was no clinically observed difference in clotting or measured blood loss. 13 Diclofenac after hip surgery (as the sole analgesic) has been shown to be more effective than on-demand IM pethidine l4 and more effective than on demand IM papaveretum,IS,16 although the methodology of the latter study has been disputed. 17 In our study we compared the combined use of IM diclofenac and continuous IV infusion of papaveretum with continuous IV papaveretum alone.
PATIENTS AND METHODS
Sixty patients aged 16 to 75 years, undergoing either total hip or knee replacement surgery, were studied. Only patients assessed preoperatively to be ASA I or 11 were included. Patients were excluded if they had a known intolerance to non-steroidal antiinflammatory drugs, a previous history of peptic Patients were randomly allocated to receive either IM placebo (Group A) or IM diclofenac injections (Group B). Preoperatively a visual analogue pain score system (VAS) based on a standard 100 mm straight line was explained to the patients and a pre-surgery score obtained as was an observed pain rating based on a four point scale: o = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain.
A standardised premedication of papaveretum (0.2-0.3 mg/kg-I) and glycopyrrolate (0.06 mg.kg-I ) was given. Anaesthesia was induced with thiopentone 3-5 mg.kg-I and maintained with nitrous oxide, oxygen and enflurane. Neuromuscular blockade was obtained with vecuronium.
Immediately after induction an IM injection of either normal saline 3 ml as placebo or diclofenac 75 mg in 3 ml injectate was given into the opposite lower limb to the site of surgery. At the end of surgery an IV infusion of papaveretum 1.0 mg.ml-I in normal saline was commenced and run at a rate sufficient to allow the patient comfort during recovery from anaesthesia.
Patients were transferred to a high dependency ward and the papaveretum infusion maintained for 24 hours. The hourly infusion rate was varied within prescribed limits by nursing staff according to their assessment of the patients' analgesic needs. Blood pressure, pulse, temperature, respiratory rate and fluid balance were recorded hourly. Prochlorperazine IM 6.25 mg or 12.5 mg, depending on the patient age, weight and general state was given as required up to six hourly as an antiemetic.
Twelve hours after the initial injection, a second IM dose of either placebo or diclofenac was given.
The following data was recorded at 4, 8, 12 and 24 hours from the time of induction:
1. total dosage of papaveretum by infusion in mg, 2. visual analogue pain score, 3. observed pain rating, Total opiate dosage -mean (SEM).
Placebo Dic10fenac
Papaveretum dose (mg) 60.8 (3.69) 44.9 (2.97) .p= 0.001 (Students t test).
4. estimated total blood loss from the commencement of the procedure to the end of the 24-hour postoperative period made by adding the intraoperative loss (suction and weighed swabs) to the measured postoperative loss in the redivac drains, and 5. number of doses of antiemetic required during the study period. The data from the two groups was assessed by Students' t test, Mann-Whitney U-test and chisquared test as appropriate.
RESULTS
All patients admitted to the trial completed it. Group A and B did not differ significantly in respect of mean age and weight and sex distribution ( Table 1) .
Patients in Group B (receiving diclofenac) had a significant reduction in total papaveretum dosage (p= 0.001) ( Figure 1 and Table 2 ). Although Group B patients also had decreased V AS scores this difference only reached statistical significance four hours postoperatively (P < 0.05 Mann Whitney U test) ( Figure 2 ). Maximum observed pain scores during the 24-hour postoperative period were significantly reduced in Group B patients (P< 0.05) ( Table 3 ) who also showed a reduced requirement for antiemetic injections (Table 4) . Measured blood loss did not significantly differ between the diclofenac and control groups ( Table 5 ).
DISCUSSION
Pain after joint replacement is due in large part to the resulting peripheral tissue injury with accompanying soft tissue inflammation and sensitisation of nociceptors by release of biochemicals including prostaglandins and other arachidonic acid metabolites. 18 ,19 This may be associated with secondary hyperalgesia in uninjured tissue mediated both by a peripheral 2 0-22 and a central mechanism. 23 ,24 There is evidence that if the afferent neuronal barrage to the spinal cord resulting from peripheral tissue injury can be blocked or reduced, the hyperexcitable central state in the dorsal horn of spinal cord which results can be prevented. 25 • 26 In addition, the dose of opiate required to suppress pain once hyperexcitation has occurred is higher than that required to control it in the normal state. 27 The rationale for using non-steroidal antiinflammatory drugs prior to the commencement of surgery and, in conjunction with an opiate infusion, in the postoperative period, is to pre-empt these effects of peripheral tissue injury while still modulating central pain transmission with the opiate.
In addition there is evidence, in recent animal experiments, that the newer, highly potent, nonsteroidal anti-inflammatory drugs such as diclofenac may also have important central analgesic effects mediated by depression of C fibre activity in the thalamus. 28 The importance of attacking the problem of pain not only at the peripheral site where it is initiated, but also centrally and, ideally, by pre-empting the sensitisation of the dorsal horn, was emphasised by Dubner in a recent editorial. 29 In this study we have shown that diclofenac, in combination with a continuous IV infusion of papaveretum, provides better analgesia with a reduction in opiate requirements compared with an infusion of papaveretum alone. There was no increase in measured blood loss accompanying this improvement confirming the finding in the study by McGlew et al. 13 No patient in our study had any serious gastrointestinal disturbance in contrast to Buchanan et al. 15 when diclofenac administration was continued to 48 hours.
We commend the use of diclofenac injections as . a supplement to opiate analgesia for all patients having major joint replacement surgery, unless a specific contraindication such as non-steroidal anti-inflammatory drug intolerance or peptic ulceration exists. 
